Publications by authors named "Fu Lu Ai"

Claim this Profile
C
Construction and Validation of a Novel Nomogram for Predicting the Risk of Metastasis in a Luminal B Type Invasive Ductal Carcinoma Population.
Xu Dong Zhu, Jia Hui Yu, Fu Lu Ai, Yue Wang, Wu Lv

World J Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biofeedback therapy combined with Baduanjin on quality of life and gastrointestinal hormone level in patients with colorectal cancer.
Xiao-Ding Zhou, Hong-Gang Wei, Fu-Lu Ai

World J Gastrointest Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of cognitive behavior therapy combined with Baduanjin in patients with colorectal cancer.
Zheng-Gen Lin, Ren-Dong Li, Fu-Lu Ai, Song Li, Xin-An Zhang

World J Gastrointest Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma.
Wen-Heng Zheng, Tao Yu, Ya-Hong Luo, Ying Wang, Ye-Fu Liu, Fu-Lu Ai

World J Gastrointest Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermedin promotes hepatic carcinoma cell proliferation through upregulation of miR-155.
Hai Shang, Zhi Qiang Hao, Xi Bo Fu, Xiang Dong Hua, Zuo Hong Ma, Fu Lu Ai

Int J Clin Exp Pathol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermedin promotes hepatocellular carcinoma cell proliferation through the classical Wnt signaling pathway.
Hai Shang, Zhi Qiang Hao, Xi Bo Fu, Xiang Dong Hua, Zuo Hong Ma, Fu Lu Ai

Oncol Lett· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis